NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200

Por Fu, Junsheng, Rodova, Mariana, Nanta, Rajesh, Meeker, Daniel, Van Veldhuizen, Peter J., Srivastava, Rakesh K., Shankar, Sharmila
Publicado em 2013

Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1

Por Dhar, Kakali, Dhar, Gopal, Majumder, Monami, Haque, Inamul, Mehta, Smita, Van Veldhuizen, Peter J, Banerjee, Sushanta K, Banerjee, Snigdha
Publicado em 2010

Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis

Por Haque, Inamul, Mehta, Smita, Majumder, Monami, Dhar, Kakali, De, Archana, McGregor, Douglas, Van Veldhuizen, Peter J, Banerjee, Sushanta K, Banerjee, Snigdha
Publicado em 2011

Prostate-Specific Antigen and Prostate-Specific Antigen Velocity as Threshold Indicators in (11)C-Acetate PET/CTAC Scanning for Prostate Cancer Recurrence

Por Dusing, Reginald W., Peng, Warner, Lai, Sue-Min, Grado, Gordon L., Holzbeierlein, Jeffrey M., Thrasher, J. Brantley, Hill, Jacqueline, Van Veldhuizen, Peter J.
Publicado em 2014

Leiomyosarcoma of the inferior vena cava: a case report and review of the literature

Por Reddy, Venkataprasanth P, VanVeldhuizen, Peter J, Muehlebach, Gregory F, Dusing, Reginald W, Birkbeck, James P, Williamson, Stephen K, Krishnan, Leela, Meyers, David G
Publicado em 2010

A PHASE II STUDY OF GEMCITABINE AND CAPECITABINE IN PATIENTS WITH ADVANCED RENAL CELL CANCER (RCC): SOUTHWEST ONCOLOGY GROUP STUDY S0312

Por Van Veldhuizen, Peter J., Hussey, Michael, Lara, Primo N., Mack, Philip C., Gandour-Edwards, Regina, Clark, Joseph I., Lange, Marianne K., Crawford, E. David
Publicado em 2009

S9511: A Southwest Oncology Group Phase II Study of Trimetrexate, 5FU, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach

Por Blanke, Charles D., Chansky, Kari, Christman, Kathy L., Hundahl, Scott A., Issell, Brian F., Van Veldhuizen, Peter J., Budd, G Thomas, Abbruzzese, James L., Macdonald, John S.
Publicado em 2010

Clinical and Correlative Results of SWOG S0354: a Phase II Trial of CNTO328 (siltuximab), a Monoclonal Antibody against Interleukin-6 (IL-6), in Chemotherapy Pre-treated Patients w...

Por Dorff, Tanya B., Goldman, Bryan, Pinski, Jacek K., Mack, Philip C., Lara, Primo N., Van Veldhuizen, Peter J., Quinn, David I., Vogelzang, Nicholas, Thompson, Ian M., Hussain, Maha
Publicado em 2010

A Second Generation 2-Methoxyestradiol Prodrug Is Effective Against Barrett's Adenocarcinoma in a Mouse Xenograft Model

Por Kambhampati, Suman, Rajewski, Roger A., Tanol, Mehmet, Haque, Inamul, Das, Amlan, Banerjee, Snigdha, Jha, Saheli, Burns, Douglas, Reyes, Emma Borrego-Diaz, Van Veldhuizen, Peter J., Banerjee, Sushanta K.
Publicado no Mol Cancer Ther (2013)

Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma o...

Por Smith, David C., Tangen, Cathy M., Hussain, Maha H.A., Van Veldhuizen, Peter J., Harrer, Grant W., Stuart, Robert K., Mills, Glenn M., Vogelzang, Nicholas J., Thompson, Ian M.
Publicado em 2011

Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer

Por Huang, Chao H., Williamson, Stephen K., Neupane, Prakash, Taylor, Sarah A., Allen, Ace, Smart, Nora J., Uypeckcuat, Adelina M., Spencer, Sarah, Wick, Jo, Smith, Holly, Van Veldhuizen, Peter J., Kelly, Karen
Publicado no Front Oncol (2016)

A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells as a Blood-Based Tumor Marker in Patients with Extensive Small-Cell Lung Cancer

Por Huang, Chao H., Wick, Jo A., Sittampalam, Gurusingham Sitta, Nirmalanandhan, Victor Sanjit, Ganti, Apar Kishor, Neupane, Prakash C., Williamson, Stephen K., Godwin, Andrew K., Schmitt, Sarah, Smart, Nora J., Spencer, Sarah, Van Veldhuizen, Peter J.
Publicado em 2014

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

Por Quinn, David I., Tangen, Catherine M., Hussain, Maha, Lara, Primo N., Goldkorn, Amir, Moinpour, Carol M., Garzotto, Mark G., Mack, Philip C., Carducci, Michael A., Monk, J. Paul, Twardowski, Przemyslaw W., Van Veldhuizen, Peter J., Agarwal, Neeraj, Higano, Celestia S., Vogelzang, Nicholas J., Thompson, Ian M.
Publicado no Lancet Oncol (2013)

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase 3 metastatic castration resistant prostate cancer trial

Por Goldkorn, Amir, Ely, Benjamin, Tangen, Catherine M., Tai, Yu-Chong, Xu, Tong, Li, Hongli, Twardowski, Przemyslaw, Van Veldhuizen, Peter J., Agarwal, Neeraj, Carducci, Michael A., Monk, J. Paul, Garzotto, Mark, Mack, Philip C., Lara, Primo, Higano, Celestia S., Hussain, Maha, Vogelzang, Nicholas J., Thompson, Ian M., Cote, Richard J., Quinn, David I.
Publicado no Int J Cancer (2014)

Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prosta...

Por Goldkorn, Amir, Ely, Benjamin, Quinn, David I., Tangen, Catherine M., Fink, Louis M., Xu, Tong, Twardowski, Przemyslaw, Van Veldhuizen, Peter J., Agarwal, Neeraj, Carducci, Michael A., Monk, J. Paul, Datar, Ram H., Garzotto, Mark, Mack, Philip C., Lara, Primo, Higano, Celestia S., Hussain, Maha, Thompson, Ian Murchie, Cote, Richard J., Vogelzang, Nicholas J.
Publicado em 2014